KBC Group NV Purchases 12,793 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

KBC Group NV raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 149,440 shares of the biopharmaceutical company's stock after buying an additional 12,793 shares during the quarter. KBC Group NV owned approximately 0.14% of Regeneron Pharmaceuticals worth $94,779,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of REGN. Brighton Jones LLC increased its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after purchasing an additional 686 shares during the period. IFP Advisors Inc increased its holdings in shares of Regeneron Pharmaceuticals by 17.2% during the fourth quarter. IFP Advisors Inc now owns 368 shares of the biopharmaceutical company's stock valued at $262,000 after purchasing an additional 54 shares during the period. SVB Wealth LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $707,000. Fisher Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 16.5% during the fourth quarter. Fisher Asset Management LLC now owns 5,890 shares of the biopharmaceutical company's stock worth $4,197,000 after acquiring an additional 833 shares during the period. Finally, US Bancorp DE grew its holdings in Regeneron Pharmaceuticals by 21.6% during the fourth quarter. US Bancorp DE now owns 6,066 shares of the biopharmaceutical company's stock worth $4,321,000 after acquiring an additional 1,078 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on REGN shares. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. The Goldman Sachs Group lowered their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Citigroup lowered their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 2nd. Finally, Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $822.58.

Regeneron Pharmaceuticals Price Performance

Shares of REGN remained flat at $521.00 during trading hours on Friday. The stock had a trading volume of 1,607,735 shares, compared to its average volume of 899,578. The company has a market cap of $56.25 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 1.91 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average of $554.18 and a 200 day moving average of $631.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $9.55 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.68%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.